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Introduction
Headache disorders are ubiquitous, common, disabling
and to a very large extent treatable in primary care.
Migraine headaches affect 12% of the adult population
worldwide and cause significant economic loss due to
decreased workplace productivity. Although interactions
between pharmacists and individuals with headache are
common, few pharmacists receive adequate training
regarding migraine therapy. There are several misconcep-
tions that hinder effective care, such as that migraine is a
vascular disease, triptans cause rampant cardiac-related
morbidity and even mortality. The last decade’s experi-
ence with triptans in more than half a billion people
worldwide reveals a benign adverse-effect profile, partic-
ularly when taken early in an attack. Published reports and
real-world experiences illustrate that these drugs do not
merit fears of triptan-induced cardiac consequences in
appropriately selected individuals. Society’s productivity
loss due to migraine is measured in billions of dollars.
Restoring a patient’s ability to function normally is now
recognised as the primary treatment goal, not merely
relieving pain. Thus, the over-reliance on “pain killer”
drugs such as butalbital-containing products and the con-
tinued underutilisation of migraine-specific drugs need to
be addressed [1].
Attack treatment
One of the main problems in treating migraine is how to
treat attacks. In this situation it has been shown that strat-
ified care is more efficacious and economic than step care
strategies [2]. These results were confirmed later and a
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most relevant items in ongoing
health organisation procedures.
The choice of a new or an old ther-
apeutic treatment depends on a
number of factors and the evalua-
tion of the cost, in terms of eco-
nomics, but also in terms of quali-
ty of life and type of facilities nec-
essary for one treatment are crucial
criteria. Therefore, we have to con-
sider in evaluating treatment
strategies not only the activity of a
drug in reaching the main end-
points, (i.e., pain free or headache
relief) but also the safety and per-
ception of safety by patients, and
the cost effectiveness, including
indirect costs compared with per-
sonal and social benefits. Because
it is reasonable that a subgroup of
migraine patients may have a clini-
cally progressive disorder, studies
should be necessary to assess
strategies for migraine treatments.
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stratified care strategy, which included zolmitriptan, was
the dominant strategy and was unequivocally more cost
effective from a societal perspective than either step care
strategy. When the uncertainty around these means was
considered, stratified care had the highest probability of
being cost effective [3].
This approach was of high impact because of the
common view to delay more potent (and often effective)
drugs until verified failure of mild analgesics or less
specific drugs.
A composite efficacy/tolerability end-point was used
to compare the cost effectiveness, from the perspective
of a US healthcare payer, of almotriptan and sumatriptan
in the treatment of an acute migraine attack [4].
Almotriptan was economically superior to sumatriptan in
the treatment of a migraine attack (US$ 82 vs. 133 per
attack, respectively).
Another study compared the direct medical costs of
managing chest symptoms in patients treated for acute
migraine with almotriptan or sumatriptan using an eco-
nomic model [5]. The economic model of this study com-
bined data from a randomised clinical trial that compared
almotriptan with sumatriptan and data from a practice pat-
tern survey of physicians. The average direct medical cost
of managing chest symptoms that appeared after the first
dose of an oral triptan was $0.22 for patients treated with
almotriptan and $1.64 for patients treated with sumatrip-
tan, a difference of $1.42 per patient.
Adelman [6] compared the cost of packages of triptans
and the number of pills for each package, and published a
list of cost per pill as follows:
Current triptan retail prices (per unit) include: Amerge
1 and 2.5 mg, $17.78; Axert 6.25 and 12.5 mg, $16.31;
Frova 2.5 mg, $13.89; Imitrex 50 mg, $14.96; Imitrex 100
mg, $14.41; Imitrex Nasal Spray 20 mg, $21.61; Imitrex
SQ 6 mg, $50.26; Maxalt 5 and 10 mg, $15; Maxalt-MLT
5 and 10 mg, $15; Relpax 40 mg, $13.58; Zomig 2.5 mg,
$13.67; Zomig 5 mg, $15.89; Zomig-ZMT 2.5 mg,
$13.67; and Zomig-ZMT 5 mg, $15.89.
In conclusion, practitioners can optimise the use of
healthcare dollars without compromising quality of care
through awareness of cost-saving treatment strategies, as
well as price variations among medications.
Also, the evaluation of cost-related side effects can be
considered, and an economic model has been developed to
estimate cost of chest-pain-related care in migraine patients
receiving almotriptan 12.5 mg compared with those receiv-
ing sumatriptan 50 mg [7]. Among a cohort of 1390
patients, the incidence of chest-pain-related diagnoses
increased significantly (43.6%) with sumatriptan, from 110
during the baseline period to 158 during the treatment peri-
od (p=0.003). Aggregate costs for chest-pain-related diag-
noses and procedures increased 33.1%, from $22 713 to
$30 234. Sumatriptan treatment was associated with a 3-
fold increase in payments for services for painful respira-
tion and other chest pain. The model predicted $11 215 in
direct medical cost savings annually per 1000 patients treat-
ed with almotriptan instead of sumatriptan.
In a recent article, the benefit of intranasal sumatriptan
in adolescents was evaluated. The results of published
papers are listed [8]:
1. The reference first-line drug therapy for migraine
attacks in adolescents is a non-specific analgesic such
as paracetamol or a non-steroidal anti-inflammatory
drug like ibuprofen. Two specific analgesics are autho-
rised for use in this setting in France, namely ergota-
mine and dihydroergotamine.
2. Nasal sumatriptan is the first triptan to be licensed for
this age group in France.
3. Evaluation data includes three flawed placebo-con-
trolled trials.
4. Effects were modest at best. Only one of the three tri-
als showed that sumatriptan was more likely than
placebo to give complete pain relief within two hours.
The three trials fail to show that sumatriptan is effec-
tive against symptoms such as nausea and vomiting,
photophobia and phonophobia.
5. The principal known adverse effects of sumatriptan are
chest tightness, flushing and increased blood pressure.
6. In the only trial report containing relevant informa-
tion, an unpleasant taste was the only adverse effect
more commonly associated with sumatriptan than
with placebo.
7. Postmarketing follow-up revealed a number of serious
adverse effects, including stroke, myocardial infarc-
tion and loss of vision.
8. The packs containing 6 or 12 spray vials carry a risk of
overuse and self-induced headache.
9. In practice, sumatriptan must not be used to treat
migraine attacks in adolescents.
Dowson et al. [9] provide advice on what information
should be taken into account by the physician before
they consider switching from one triptan to another.
Switching triptans can therefore only be recommended if
the patient experiences problems such as lack of effica-
cy or intolerable side effects following repeated use of
the initial triptan. The retrospective database study
revealed that most patients who had their triptan
switched were subsequently switched again during a 15-
month review period, most usually back to their original
triptan. Overall, switching a patient’s triptan led to
increased costs (analysed as costs of medication and the
GP consultation) to the healthcare provider. These data
indicate that patients should only be switched from one
triptan to another for clinical reasons and not for per-
ceived economic reasons, i.e., cost of the medication.
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An economic evaluation of acute migraine attack treat-
ment in Spain was evaluated recently [10], by a cost-
effectiveness analysis, using 2003 prices, comparing
almotriptan 12.5 mg, eletriptan 40 mg, naratriptan 2.5 mg,
rizatriptan 10 mg, sumatriptan 50 mg, sumatriptan 100
mg, zolmitriptan 2.5 mg and zolmitriptan 5 mg. Rescue
medication use and 24-h attack relapse rates were
assessed. Thirty-eight clinical trials (19 872 patients) were
used to assess triptan effectiveness.
At the end of the study eletriptan 40 mg and sumatriptan
50 mg showed the lowest costs per successfully treated
attacks with 2 h anti-migraine response (€ 16.50 and €
17.44) and with 24 h sustained pain free (€ 31.47 and €
33.61), while the lowest costs per attack that was pain free
at 2 h were observed with rizatriptan 10 mg (€ 21.36) and
eletriptan 40 mg (€ 22.99). Considering the cost-effective-
ness measurements assessed, eletriptan 40 mg was the most
cost-effective triptan in the majority of economic analyses
carried out.
The final impact of migraine cost and an analysis of
this aspect was carried out by Stang in 2004 [11], who
concluded that migraine families incur far higher direct
and indirect healthcare costs than non-migraine families,
with variation depending on which family member is the
clinically detected migraineur.
Prophylactic treatment
An increasing problem is the evaluation of the impact of
prophylactic treatment on use and, therefore, the cost of this
strategy in treating headaches. A retrospective administra-
tive database study was conducted to measure the direct
(pharmacy and medical) costs of migraine-related health-
care services in moderate-to-severe migraine patients treat-
ed with drug prophylaxis compared with migraine patients
who are not treated with drug prophylaxis [12].
Thirty-nine percent of new triptan users received only
1 triptan claim during the 12-month follow-up period,
accounting for 11.5% of the total triptan cost incurred by
the health plan for this cohort. For new triptan users, trip-
tan use in the first or second quarter was correlated with
triptan use in the entire 12-month follow-up period
(r=0.187 and 0.279, respectively). The mean migraine-
related pharmacy cost per patient during the follow-up
was $871; however, continuous users had mean costs
($1505) nearly 3 times the mean costs for new users
($506, p<0.05). The average treatment effect of drug pro-
phylaxis in moderate-to-severe migraine patients was a
decrease of $560 ($514–$607) per patient per year in
1998–2001 dollars. High utilisers of migraine therapy can
be identified early in treatment. Drug prophylaxis for
migraine is cost saving, and an intervention programme
that increases the use of migraine prophylaxis in potential
candidates could be cost beneficial.
Similar results were obtained by Adelman [13], who
examined the prices of different medications. In spite of
similar effectiveness, the costs of these treatments vary
tremendously. Costs of migraine prophylactic medications
vary within and between categories.
Certain strategies may be employed to reduce the cost
of care:
1. choose generic options when possible;
2. maximise doses of medications so that single larger
tablets are used instead of multiple smaller tablets;
3. employ pill splitting; and
4. choose medications that may also treat comorbid med-
ical conditions such as hypertension or depression in
order to reduce or eliminate secondary medications.
The anti-epileptic drugs (AEDs) are rapidly emerging
as first-line agents for migraine prevention. The cost of
these medications can be substantial. Only one AED (val-
proic acid) considered effective for migraine prevention is
available as a generic in the USA. As a group, the costs for
the AEDs are greater than the antihypertensives and anti-
depressants.
Generic beta-blockers and tricyclic antidepressants
tend to be effective and inexpensive. The exceptions
include long-acting propranolol, protriptyline and trim-
ipramine, which are not available in generic form and are
more expensive.
Among the newer antidepressant medications used for
migraine prevention, buproprion, fluoxetine, fluvoxamine
and paroxetine are available as generics. In cases where an
extended-release form is only available as a non-generic
and the short-acting formula is available as a generic (e.g.,
buproprion), the generics’ lower cost per tablet must be bal-
anced with the possible need for multiple dosing, increased
adverse events, and decreased compliance.
Many other drugs are employed in headaches treat-
ment, and some are used in chronic headaches (migraine
derived or tension-type headaches), which have a high
impact on quality of life.
Recently, to evaluate the efficacy of mirtazapine, 24
non-depressed patients with chronic tension-type
headache were included in a randomised, double-blind,
placebo-controlled, crossover trial. All patients had tried
numerous other treatments [14].
A good example of a risk-benefit ration is the use of
oral contraceptives (OCs) in migraine [15]. Is this intake
associated with an increased risk of ischaemic stroke?
Migraine per se is not a contraindication for OCs use; but
all OCs, even those with low oestrogen content, are a
major risk for venous thrombosis, particularly in women
with hereditary thrombophilia.
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Cardiovascular risk-assessment algorithms discussed
elsewhere in this supplement suggest that patients at low
risk (1 or no risk factors) of coronary heart disease can be
prescribed triptans without the need for a more intensive
cardiovascular evaluation. Conversely, patients with estab-
lished coronary heart disease or coronary heart disease risk
equivalents should not be prescribed triptans according to
the current prescribing recommendations. Patients at inter-
mediate risk (2 or more risk factors) of coronary heart dis-
ease require cardiovascular evaluation before triptans can
be prescribed. Cardiovascular risk-assessment guidelines
should be evaluated in the context of this limitation [16].
Conclusions
Usually suggestions are set out for their optimal manage-
ment, although many of these are necessarily based more
on expert opinion than on formal evidence, because clini-
cal trials have covered only narrow areas of headache
treatment [17]. Most people whose lives are adversely
affected by headache disorders benefit from drug inter-
ventions, either acute or preventative, but other forms of
treatment are always important and should never be over-
looked. An important disorder is entirely iatrogenic: its
recognition is crucial to its effective management, which
requires medication withdrawal. Future research is need-
ed not only into the mechanisms of headache causation, as
a prerequisite for the development of better treatments,
but also into public health aspects seeking an explanation
of (and remedy for) the low priority given worldwide to
headache-related healthcare despite the severe human and
socioeconomic consequences.
Future epidemiological studies should focus on identi-
fying patients who are at higher risk for progression and
on assessing the impact of intervention strategies on dis-
ease progression [18].
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